Clinical Trial Update: An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)

View source ↗

Summary

This is an open-label, multicenter expanded access protocol to provide leronlimab to patients with locally advanced or metastatic triple-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Leronlimab (leronlimab)

Snippet

Sponsor: CytoDyn, Inc. | Conditions: TNBC, TNBC - Triple-Negative Breast Cancer | Status: AVAILABLE